Agonists of the cannabinoid type 2 receptor (CBR2), like ∆9THC, the novel ∆9-THCP, and the synthetic HU910, HU308 and JWH133, bind to the CBR2 to treat COVID-19 through immunopsuppression and reduction of pro-inflammatory cytokines. Cannabidiol (CBD) also exerts anti-inflammatory and immunosuppressive effects independently of the CBR2, by increasing anandamide levels.

Proper stimulation of their CB2 receptor, could be proposed to improve COVID-19 patients’ conditions with a double function: to repair tissue damages on stem cells and to drive immune response in a protective direction immunomodulating cells.